Eurand Granted FDA Approval for Zenpep
Eurand Granted FDA Approval for Zenpep
August 28, 2009
PHILADELPHIA, PA, Aug 28, 2009 -- Eurand N.V., a specialty
pharmaceutical company, today announced U.S. Food and Drug
Administration (FDA) approval of its New Drug Application (NDA) for
Zenpep (pancrelipase) Delayed-Release Capsules for the treatment of
exocrine pancreatic insufficiency (EPI) in patients with cystic
fibrosis (CF) or other conditions. Zenpep is the only FDA-approved
pancreatic enzyme product (PEP) that has been evaluated in clinical
studies in adults and children -- including children
August 28, 2009
PHILADELPHIA, PA, Aug 28, 2009 -- Eurand N.V., a specialty
pharmaceutical company, today announced U.S. Food and Drug
Administration (FDA) approval of its New Drug Application (NDA) for
Zenpep (pancrelipase) Delayed-Release Capsules for the treatment of
exocrine pancreatic insufficiency (EPI) in patients with cystic
fibrosis (CF) or other conditions. Zenpep is the only FDA-approved
pancreatic enzyme product (PEP) that has been evaluated in clinical
studies in adults and children -- including children
Comentarios
Publicar un comentario